Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis

Trans R Soc Trop Med Hyg. 1996 May-Jun;90(3):317-8. doi: 10.1016/s0035-9203(96)90270-9.

Abstract

The rapidity and efficacy of a short course of liposomal amphotericin B was evaluated in 29 children affected by visceral leishmaniasis (Leishmania infantum). Their overall health status was assessed using the prognostic inflammatory and nutritional index (PINI), and their haematological status by the reticulocyte count and haemoglobin blood levels. All these quantities were measured on day 0, and 3 and 10 d after starting therapy. A significant decrease of inflammatory signs, associated with an improved reticulocyte count, was recorded after 3 d of therapy. A significant increase of haemoglobin levels was also observed 10 d after the start of treatment. The early reduction of inflammatory signs and the improvement of bone marrow function in most patients confirmed the validity of amphotericin B therapy. The PINI score is helpful in assessing the severity of visceral leishmaniasis and the follow-up of its treatment.

MeSH terms

  • Adolescent
  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Anemia / complications
  • Anemia / drug therapy
  • Animals
  • Antiprotozoal Agents / administration & dosage
  • Antiprotozoal Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Drug Carriers
  • Female
  • Humans
  • Infant
  • Italy
  • Leishmania infantum*
  • Leishmaniasis, Visceral / complications
  • Leishmaniasis, Visceral / drug therapy*
  • Liposomes
  • Male
  • Severity of Illness Index

Substances

  • Antiprotozoal Agents
  • Drug Carriers
  • Liposomes
  • liposomal amphotericin B
  • Amphotericin B